IP Library Patent Application 17064847
Patent Application
App. No. 17/064,847

Methods and Compositions for Improving Quality of Life and Increasing Activity in Aging and Chronically Ill Mammals

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/064,847
Abstract

Methods for improving quality of life and/or increasing activity in an aging and/or chronically ill mammal via administration of a composition of egg yolk powder are provided. In some embodiments, additional agents improving quality of life and/or increasing activity in an aging and/or chronically ill mammal are administered in combination with the egg yolk powder.

Claims (20)

1 . A method for alleviating and/or inhibiting a negative effect on quality of life and/or activity in an aging and/or chronically ill mammal, said method comprising administering to the aging and/or chronically ill mammal a composition comprising egg yolk powder.

2 . The method of claim 1 wherein the negative effect comprises muscle loss, weakness, stiffness, decreased energy and/or decreased mobility.

3 . The method of claim 1 wherein administration of the composition reduces muscle loss, reduces weakness, reduces stiffness, increases strength, increases energy and/or increases mobility in the aging and/or chronically ill mammal.

4 . The method of claim 1 wherein the negative effect results from rheumatoid or osteoarthritis.

5 . The method of claim 1 wherein the negative effect results from hip dysplasia.

6 . The method of claim 1 wherein the negative effect results from long-term oral corticosteroid administration.

7 . The method of claim 1 wherein the negative effect results from a chronic disease associated with lean body mass wasting.

8 . The method of claim 7 wherein the chronic disease is kidney disease, liver disease, cancer, cardiac disease, cachexia, HIV/AIDS, amyotrophic lateral sclerosis (ALS), dermatomyositis, Guillian-Barr syndrome, multiple sclerosis, muscular dystrophy, neuropathy, osteoarthritis, polio, polymyositis, rheumatoid arthritis or spinal muscular atrophy.

9 . The method of claim 1 wherein the mammal is a human.

10 . The method of claim 1 wherein the mammal is a dog.

11 . The method of claim 10 wherein the negative effect results from a chronic infectious disease associated with muscle loss or a polyneuropathy.

12 . The method of claim 11 wherein the polyneuropathy comprises Coonhound paralysis, idiopathic polyradiculoneuritis or chronic inflammatory demyelinating polyneuropathy.

13 . The method of claim 11 wherein the chronic infectious disease comprises hepatozoonosis or leishmaniasis.

14 . The method of claim 1 wherein the composition comprises a fertilized egg yolk derived product.

15 . The method of claim 14 wherein the fertilized egg yolk derived product is FORTETROPIN.

16 . . The method of claim 1 wherein the composition comprises avian follistatin.

17 . The method of claim 1 further comprising administering to the aging and/or chronically ill mammal one or more second agents which alleviates and/or inhibits a negative effect on quality of life and/or activity in the aging and/or chronically ill mammal.

18 . The method of claim 17 wherein the one or more second agents is selected from cannabidiol, green-lipped mussel, glucosamine, chondroitin sulfate, omega-3 fatty acids, Boswellia serrata, branched-chain amino acids, creatine, β-hydroxy β-methylbutyric acid, green tea extract, pomegranate extract, L-carnitine, L-arginine, L-glutamine, krill, curcumin, B-alanine, Vitamin A, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, folic acid, riboflavin, niacin, coenzyme Q10, iron, magnesium, selenium, zinc, resveratrol and/or pterostilbene.

19 . The method of claim 1 wherein the composition further comprises one or more second agents which alleviates and/or inhibits a negative effect on quality of life and/or activity in the aging and/or chronically ill mammal.

20 . The method of claim 19 wherein the one or more second agents is selected from cannabidiol, green-lipped mussel, glucosamine, chondroitin sulfate, omega-3 fatty acids, Boswellia serrata, branched-chain amino acids, creatine, βhydroxy β-methylbutyric acid, green tea extract, pomegranate extract, L-carnitine, L-arginine, L-glutamine, krill, curcumin, B-alanine, Vitamin A, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, folic acid, riboflavin, niacin, coenzyme Q10, iron, magnesium, selenium, zinc, resveratrol and/or pterostilbene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2022
From: MYOS RENS TECHNOLOGY INC.
To: MYOS CORP.
Reel/Frame 059426/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2021
From: MANNELLO, JOSEPH; DARIANI, MAGHSOUD; PADLIYA, NEERAV D.
To: MYOS RENS TECHNOLOGY INC.
Reel/Frame 055329/0130 →